AndroGel (Testosterone Topical) Erythrocytosis: When It Doesn't Go Away

Why AndroGel Raises Red Blood Cell Counts

Testosterone stimulates erythropoiesis through two well-characterized pathways, and transdermal formulations like AndroGel are not exempt from either. The magnitude is typically smaller than with intramuscular testosterone, but "smaller" does not mean "absent," and for men who start with borderline hematocrit, even a modest rise can become clinically significant.

The EPO Pathway

Testosterone acts on renal peritubular cells to increase erythropoietin (EPO) secretion. EPO then binds burst-forming unit erythroid (BFU-E) progenitors in bone marrow, accelerating the production of mature red blood cells. This pathway is dose-dependent: higher free testosterone levels generate stronger EPO signals. Because AndroGel delivers testosterone transdermally at a slower absorption rate than intramuscular depots, peak free testosterone is generally lower, which is part of why transdermal gel carries a lower erythrocytosis risk per milligram of testosterone delivered compared to injections.

The Hepcidin Suppression Pathway

Testosterone also suppresses hepcidin, the master regulator of iron absorption and recycling. Lower hepcidin allows more iron to enter the circulation, feeding the expanded erythroid precursor pool that EPO has already stimulated. This second mechanism partly explains why some men see hematocrit continue rising for weeks after a dose adjustment. The iron supply chain stays open even as EPO signal starts to taper.

How Transdermal Differs from Injectable Testosterone

A 2010 Endocrine Society meta-analysis found that intramuscular testosterone increased hematocrit by a mean of 3.2 percentage points vs. Roughly 1.5 percentage points for transdermal preparations. The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy notes that hematocrit elevation is formulation-sensitive and recommends reducing dose or switching delivery route when hematocrit exceeds 54%. Still, a subset of transdermal users crosses that threshold, and the question this article focuses on is what happens when counts don't come down after the obvious first steps.

How Common Is Erythrocytosis with AndroGel Specifically?

Exact prevalence depends on the starting hematocrit, the prescribed dose, and the duration of therapy. Across multiple controlled trials, the incidence picture is clearer than many patients realize.

Data from Controlled Trials

The Testosterone Trials (TTrials), a coordinated set of seven double-blind placebo-controlled studies in men aged 65 and older using testosterone gel 1% (the same active formulation as AndroGel 1%), found that hematocrit above 54% occurred in 7.1% of testosterone-treated men vs. 1.7% of placebo-treated men over 12 months (P<0.001). That four-fold relative increase is clinically meaningful.

In the earlier Testosterone in Older Men with Mobility Limitations (TOM) trial, 23% of men receiving testosterone gel developed a hematocrit of 52% or higher, compared with 5% in the placebo arm. The TOM trial was stopped early for cardiovascular safety signals, partly because elevated hematocrit was felt to contribute to thrombotic risk.

FAERS Postmarketing Reports

The FDA Adverse Event Reporting System (FAERS) database contains several hundred cases of erythrocytosis or polycythemia coded against AndroGel specifically. These reports are subject to underreporting bias, but the pattern across postmarketing surveillance is consistent with trial data: onset typically within 3 to 6 months, and a subset of cases where counts did not normalize after drug cessation, prompting secondary workup.

Who Is at Highest Risk?

Men who start AndroGel with a baseline hematocrit already above 48%, men with undiagnosed obstructive sleep apnea, heavy smokers, and men at high altitude all carry elevated baseline risk. Sleep apnea alone raises hematocrit through nocturnal hypoxia-driven EPO release, and adding exogenous testosterone creates an additive erythropoietic stimulus.

When Does Erythrocytosis Resolve After Stopping or Reducing AndroGel?

This is the question most patients actually want answered. The short answer: for most men, hematocrit begins declining within 6 to 10 weeks of stopping or meaningfully reducing AndroGel, but full normalization can take 3 to 6 months. A minority of patients do not normalize within that window.

Typical Resolution Timeline

Red blood cells survive roughly 120 days in circulation. Once EPO stimulus drops, new RBC production slows, but existing cells complete their natural lifespan before being cleared. This means even a complete cessation of AndroGel does not produce an immediate hematocrit drop. Expect the following rough trajectory after stopping gel entirely:

• Weeks 2 to 4: Reticulocyte count starts to fall, indicating reduced production pressure.
• Weeks 6 to 10: Hematocrit begins a measurable decline (typically 1 to 3 percentage points).
• Months 3 to 6: Hematocrit usually returns to pre-treatment baseline.

A dose reduction rather than full cessation produces a shallower and slower decline. If a patient cuts from AndroGel 1.62% (81 mg/day) to 40.5 mg/day, the EPO signal is reduced but not eliminated, so hematocrit may plateau at an intermediate level rather than trending clearly downward.

The "Doesn't Resolve" Scenario

Persistent elevation past 3 to 6 months after stopping AndroGel, or past 12 weeks after a meaningful dose reduction, is the clinical event this article specifically addresses. Several scenarios explain it:

1. An unmasked primary polycythemia vera. The JAK2 V617F mutation is present in approximately 95% of polycythemia vera cases. Testosterone therapy can unmask a smoldering JAK2-positive clone that was subclinical before gel started. In this scenario, stopping AndroGel removes one erythropoietic stimulus but the clonal driver continues.

2. Persistent secondary cause. Untreated sleep apnea, active smoking, COPD with hypoxemia, or high-altitude living will maintain EPO drive independent of testosterone. Removing AndroGel without treating the comorbidity will not resolve erythrocytosis.

3. Prolonged testosterone tissue retention. Topical testosterone has a depot effect in skin, but it is relatively short-lived compared to intramuscular esters. This is unlikely to explain persistence beyond 4 to 6 weeks post-cessation, but it can delay early resolution.

4. Relative resolution without normalization. Some men simply have a higher natural set point for hematocrit. A hematocrit of 52% may represent this patient's normal range. Distinguishing this from pathology requires pre-treatment baseline data.

How to Manage Persistent Erythrocytosis on AndroGel: A Step-by-Step Framework

When hematocrit stays above 54% more than 12 weeks after a dose reduction, the following structured approach reflects current guideline recommendations and clinical evidence.

Step 1: Confirm the Elevation Is Real

Hemoconcentration from dehydration can falsely raise hematocrit. Draw labs in the morning after adequate hydration, confirm with a repeat draw 1 to 2 weeks later if the first result is borderline. Confirm with a complete blood count (CBC) including red cell mass if polycythemia vera is in the differential.

Step 2: Assess for Secondary Causes

Order the following before attributing the elevation entirely to AndroGel:

• JAK2 V617F mutation PCR (screens for polycythemia vera)
• Serum EPO level (low EPO suggests primary polycythemia; elevated EPO suggests secondary cause)
• Overnight pulse oximetry or polysomnography to exclude sleep apnea
• Pulmonary function tests in smokers or patients with respiratory symptoms
• Serum ferritin and iron studies

The 2018 AUA Guidelines on Testosterone Deficiency state: "If hematocrit is greater than 54%, stop testosterone therapy until hematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnea, and resume at a reduced dose once hematocrit has normalized." This guidance treats workup and dose adjustment as simultaneous, not sequential.

Step 3: Phlebotomy

Therapeutic phlebotomy is the fastest mechanical tool for reducing hematocrit. A single 450 to 500 mL unit removal will typically drop hematocrit by 2 to 4 percentage points within 24 to 48 hours. In polycythemia management broadly, the target hematocrit is below 45% in men with cardiovascular risk factors, per EHA/ASH guidance. For TRT-associated erythrocytosis, many clinicians target below 50 to 52% as a practical threshold.

Phlebotomy can be repeated every 8 to 12 weeks as needed. Each session should be accompanied by a repeat CBC at 4 to 6 weeks to assess trajectory.

Step 4: Consider Formulation Switch

If a patient genuinely benefits from testosterone therapy and wants to continue, switching from transdermal gel to a formulation with different pharmacokinetics may help.

Options with potentially lower erythrocytosis burden include:

• Testosterone nasal gel (Natesto): Three-times-daily dosing with minimal systemic absorption beyond 2 hours per dose. A 2019 study in the Journal of Urology found that Natesto maintained testosterone levels in the normal range while producing significantly less erythrocytosis than intramuscular testosterone. Transdermal-to-nasal comparisons are limited, but the pharmacokinetic profile is favorable.
• Lower-dose AndroGel continuation (40.5 mg/day): If 81 mg/day drove erythrocytosis, some patients achieve adequate symptom control at half-dose without hitting hematocrit thresholds.
• Clomiphene citrate or enclomiphene: For men who want testosterone support without exogenous testosterone, selective estrogen receptor modulators stimulate endogenous LH/FSH production. Endogenous testosterone rise through this mechanism appears to carry lower erythrocytosis risk, though head-to-head data are limited.

Step 5: Add Aspirin If Thrombotic Risk Is Elevated

The thrombotic risk of erythrocytosis depends on hematocrit level, platelet count, age, and cardiovascular comorbidities. A Framingham-derived analysis found that hematocrit above 48% in men was independently associated with a 23% increase in cardiovascular event risk. Low-dose aspirin (81 mg/day) is routinely used in polycythemia vera to reduce thrombotic events; the same logic applies to TRT-associated erythrocytosis with ongoing elevation, though a formal RCT in this specific population has not been conducted.

The Thrombotic Risk Question

Many patients ask whether a high hematocrit from AndroGel is "really dangerous" or a lab value their clinician is worrying about unnecessarily. The risk is real, though the absolute magnitude in otherwise-healthy young men is lower than in older patients with multiple cardiovascular risk factors.

What the Evidence Shows

The Vigen et al. (2013) retrospective study in JAMA (N=8,709) found that testosterone therapy was associated with a statistically significant increase in MACE (myocardial infarction, stroke, and death) in men with pre-existing coronary artery disease. The hazard ratio was 1.29 (95% CI 1.04 to 1.58) for testosterone users vs. Non-users. Erythrocytosis-driven hyperviscosity was proposed as one contributing mechanism.

More reassuring data come from the TRAVERSE trial (N=5,246), the first prospective cardiovascular safety trial specifically designed to assess testosterone therapy in men with hypogonadism and elevated cardiovascular risk. TRAVERSE found a non-inferior cardiovascular safety profile for testosterone vs. Placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) at a median follow-up of 33 months. Notably, erythrocytosis requiring dose reduction or phlebotomy occurred in 7.5% of the testosterone arm vs. 2.3% placebo, confirming the side-effect frequency while the overall MACE signal remained neutral in this selected, monitored population.

The key phrase is "selected and monitored." TRAVERSE excluded men with hematocrit above 48% at baseline and monitored CBC every 6 months, intervening when thresholds were crossed. That is the standard of care, not a passive wait-and-see approach.

Monitoring Protocol: What Your Lab Schedule Should Look Like

The 2018 Endocrine Society Clinical Practice Guideline recommends the following CBC monitoring schedule for men on testosterone therapy:

• Baseline: CBC before starting AndroGel.
• 3 months after initiation: First follow-up CBC.
• Every 6 months for year one: Continue if hematocrit is stable below 50%.
• Annually thereafter: Once two consecutive normal results have been confirmed.

The Endocrine Society states: "We suggest checking hematocrit at baseline, at 3 to 6 months, and then annually." Men with baseline hematocrit above 48%, sleep apnea, heavy smoking history, or prior erythrocytosis on any testosterone formulation should be monitored at 6 to 8 week intervals for the first 6 months.

If hematocrit exceeds 54% at any point, the protocol shifts to the step-by-step management framework described above. Waiting until a follow-up appointment "in a few months" is not appropriate at that level.

What Patients Often Get Wrong

Assuming Gel Carries No Risk Because It's "Mild"

Topical testosterone is gentler than weekly intramuscular injections in terms of peak concentration swings, but some patients interpret "milder" as "safe to ignore lab work." A hematocrit of 56% is equally dangerous regardless of whether testosterone arrived via syringe or gel packet.

Stopping AndroGel Abruptly Without a Plan

Abrupt cessation removes the erythropoietic stimulus but does not immediately lower hematocrit, as explained above. Meanwhile, testosterone withdrawal produces fatigue, mood changes, and sexual dysfunction that can feel worse than baseline hypogonadism. A planned dose taper coordinated with serial CBC monitoring is generally preferable to a sudden stop, unless hematocrit has crossed into urgently dangerous territory (above 58 to 60%).

Attributing All Elevated Hematocrit to AndroGel

As outlined in the secondary workup above, a JAK2 mutation or untreated sleep apnea can independently drive erythrocytosis. AndroGel may be the trigger that brought hematocrit above a threshold, while the underlying driver is something else entirely. Missing that secondary cause leads to a cycle of dose adjustment and phlebotomy without addressing the actual etiology.

A Note on Hydroxyurea and Cytoreductive Therapy

In true polycythemia vera or when phlebotomy alone fails to control hematocrit, hematologists sometimes add hydroxyurea (500 to 2,000 mg/day) or ruxolitinib (a JAK1/JAK2 inhibitor) to suppress marrow production. These drugs are not standard of care for pure TRT-associated erythrocytosis, but they become relevant if the workup reveals an underlying myeloproliferative disorder. The EHA/ELN guidelines recommend cytoreductive therapy when a patient requires more than two phlebotomies per year or carries high thrombotic risk. Any patient meeting those criteria should have a hematology referral before their next dose of AndroGel.

Summary: Clinical Thresholds at a Glance

| Hematocrit | Action | |---|---| | Below 50% | Continue AndroGel at current dose. Monitor per schedule. | | 50 to 54% | Reduce AndroGel dose. Increase monitoring to every 6 to 8 weeks. Assess for sleep apnea. | | Above 54% | Stop AndroGel. Full secondary workup. Consider phlebotomy. Resume at lower dose only after normalization. | | Above 58% | Stop AndroGel immediately. Urgent phlebotomy. Hematology referral. Do not resume without specialist input. |